The human epidermal growth factor receptor 2 (HER2) protein is over-expressed due to HER2 gene amplification in 10–15% of breast cancers, leading to accelerated cell proliferation and poorer clinical outcomes prior to the routine use of HER2-directed therapies [2,3]. The gene discussed is ERBB2; the disease is breast carcinoma.